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Abstract
Background: Metaplastic breast carcinoma is a rare aggressive malignant neoplasm. The purposes of this study are
to review the pathologic features and clinical outcomes of metaplastic breast carcinoma compared to invasive
ductal carcinoma and to evaluate the prognosis of metaplastic breast carcinoma.
Methods: The cases of 55 patients with metaplastic breast carcinomapresenting between 1991 and 2006 were analyzed
and compared to the cases of 767 age-matched patients with invasive ductal carcinoma from the same time period.
Results: The group of patients with metaplastic breast carcinoma presented with a larger tumor size, lower lymph node
involvement, higher percentage of triple-negative (estrogen receptor-, progesterone receptor- and human epidermal
growth factor receptor-2-negative) cases, and Ki-67 over-expression compared with the group of patients with invasive
ductal carcinoma and triple-negative invasive ductal carcinomas. Patients in the metaplastic breast carcinoma group
tended to have more local (often chest wall) recurrences (P = 0.038) and distant (often lung) metastases (P = 0.001) than
those in the invasive ductal carcinomas group. The prognosis of metaplastic breast carcinoma was poorer than that of
invasive ductal carcinoma and triple-negative invasive ductal carcinomas; the 5-year overall survival rate was 54.5% in
metaplastic breast carcinoma versus 85.1% in invasive ductal carcinoma, and 73.3% in triple-negative invasive ductal
carcinomas (P <0.001). The 5-year disease-free survival rate was 45.5% in metaplastic breast carcinoma versus 71.2% in
invasive ductal carcinoma, and 60.3% in triple-negative invasive ductal carcinomas (P <0.001). Multivariate analysis
revealed tumor size larger than 5.0 cm, lymph node involvement and Ki-67≥14% were significantly related to 5-year
overall survival (P = 0.010; P = 0.010; P = 0.035) and 5-year disease-free survival (P = 0.020; P = 0.018; P = 0.049).
Conclusions: Metaplastic breast carcinoma shows a poorer prognosis than both invasive ductal carcinoma and triple-
negative invasive ductal carcinomas. Tumor size larger than 5.0 cm, lymph node involvement and Ki-67 ≥14% indicate a
poor prognosis in patients with metaplastic breast carcinoma.
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Background
Metaplastic breast carcinoma (MBC) is a rare malignancy
characterized by various combinations of adenocarcinoma
with mesenchymal and epithelial components. It exhibits a
variety of histopathologic patterns and appears to be both
epithelial and mesenchymal in origin. MBC accounts for
less than 1% of all breast carcinomas [1]. Because it was
not officially recognized as a distinct histopathologic
subtype until 2000, knowledge about patient demographics,
presentation, tumor characteristics, prognosis and
treatment patterns is limited. The World Health
Organization have classified MBC into pure epithelial-type
and mixed epithelial and mesenchymal type [2]. The
epithelial-type MBC is subclassified into squamous cell
carcinoma (SCC), adenosquamous carcinoma (ASC) and
adenocarcinoma with spindle cell differentiation (SPC);
mixed type MBC is subclassified into carcinosarcoma
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(CS) and carcinoma with osseous and chondroid
metaplasia (COC).
MBC differs from typical invasive ductal carcinoma
(IDC) in several pathological and clinical aspects, and
the prognosis and optimal treatment for MBC are largely
not well studied. To date, only small series and case
reports have attempted to delineate the factors that
make MBC different from more common malignant
breast cancer [3-5]. Recently, much attention has been paid
to MBC because this neoplasm is usually characterized by
a lack of estrogen receptor (ER), progesterone receptor
(PR) and human epidermal growth factor receptor-2
(HER2) over-expression, which is called triple negativity
[6]. Triple-negative breast cancer has been known to be
resistant to conventional endocrine therapy for hormone
receptor-positive breast cancer or targeted therapies such
as trastuzumab for HER2 over-expressing breast cancer
[7-9]. It has been reported that the risk of tumor
recurrence of MBC is higher than in typical breast cancer.
However, this remains controversial [10-12]. The purpose
of this study is to clarify these controversies. To this end,
we compared the clinicopathological characteristics,
management and prognosis of 55 patients with MBC
with those of 767 patients with IDC, including 131
triple-negative IDC (TN-IDC) patients, treated at the
Third Affiliated Hospital of Harbin Medical University
(3rd AHHMU) from 1991 to 2006.
We analyzed indicators that affect the prognosis of
patients with MBC and that could potentially be used




Patients were selected from the database of the Breast
Cancer Center at the 3rd AHHMU between 1991 and
2006 (7,523 patients) (Figure 1). Only patients who had
surgical pathological specimens of the primary tumor
available for review were included. Fifty-five patients had
been diagnosed with MBC and were included in this
analysis; there were no patients with distant metastasis at
the time of diagnosis. These available cases were
compared with 767 IDC cases matched for age and period
of diagnosis. The patients’ medical records were retrospect-
ively reviewed to obtain demographic, clinicopathologic,
treatment and prognostic information as well as the immu-
nohistochemistry of biologic factors such as ER, PR, HER2,
P53 and Ki-67. Patients with IDC who presented with a
recurrent tumor, metastatic disease at presentation, male
tumor, bilateral tumors, previous tumors in other sites, or
those who had previously received neoadjuvant treatment
were excluded. No patient received any therapy before
surgery. All patients were followed until death or the study
closing date (30 December 2011).
Histopathology
At initial diagnosis, all tumor specimens were reviewed by
two pathologists at the 3rd AHHMU. Tumor specimens
were histologically examined, and cases were included in
the re-review (55 MBC cases) if adenocarcinomatous
elements were identified as admixed with SCC, spindle
cell, chondroid or osseus tumor basing on hematoxylin
and eosin staining and/or immunohistochemistry
(IHC). Four-micron tissue sections, prepared from a
formalin-fixed paraffin-embedded representative of the
tumor samples, were used. The histological grade was
determined according to the modified Bloom-Richardson
classification. IHC staining for ER and PR (Zhongshan-Bio
Co., Beijing, China) was performed using a conventional
detection method and ER and PR status was evaluated
based on the percentage of positively stained nuclei [13].
Positive staining for HER2 (Zhongshan-Bio Co.) was
defined based on the percentage of tumor cells and
the intensity of membrane staining. HER2 was scored
as 0 to 3+ according to the method recommended for the
DakoHercepTest. Tumors with scores of 3 or with a >2.2-
fold increase in HER2 gene amplification as determined by
fluorescence in situ hybridization were considered to be
positive for HER2 over-expression [14]. Cells stained for
Ki-67 and P53 were counted and expressed as a percentage.
Low expression was considered as Ki-67<14% [15] and
P53<25% [5]. All protocols were reviewed and approved by
the Ethical Committee of Harbin Medical University in
Harbin, China. Informed consent was obtained from
all the patients.
For subgroup analysis, the definition of triple-negative
breast cancer was as follows: negative ER and PR by
IHC, and negative HER2 represented by an IHC score of
0 or 1+, or 2+ if not amplified by fluorescence in situ
hybridization. The cases with an IHC score of 2+ for
HER2 and no fluorescence in situ hybridization results
were excluded from the triple-negative breast cancer
group. In total, 131 of the control cases were classified
as TN-IDC.
Statistical methods
Overall survival (OS) was calculated from the date of
surgery until death or the date patients were last known
to be alive. The disease-free survival (DFS) was calculated
from the date of surgery until relapse or the date patients
were last known to be alive. The primary end points of
this study were 5-year OS and 5-year DFS. In order to
compare the clinicopathological characteristics between
the two groups, we used the Student t-test and χ2 test.
The 5-year OS and 5-year DFS rates were calculated using
the Kaplan-Meier method and comparisons were made
between MBC and control patients using the log-rank
test. For multivariate analysis, Cox regression analysis was
used. Statistical analyses were performed using SPSS 17.0
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We retrieved 55 MBC cases from the 3rd AHHMU
database, representing 0.73% of the 7,523 breast cancer
cases. All patients were female, with a median age of 50
years (range, 24 to 71 years). The median tumor size was
5.0 cm (range, 1.5 to 20.0 cm). ASC was the most
common histological subtype of MBC (N = 16), followed
by SCC (N = 14), SPC (N = 12), CS (N = 10) and COC
(N = 3). Clinicopathological features and treatment were
analyzed for 55 patients with MBC and 767 patients
with IDC (Table 1).
The MBC group presented with a significantly larger
tumor size than the IDC group (>T2, 80% versus 48%,
P <0.001) and with less nodal metastasis (negative
nodal status, 64% versus 41%, P = 0.001). More patients in
the MBC group had stage III disease at diagnosis (29%
versus 11%, P = 0.001). The MBC group had significantly
more cases with no hormone receptors or HER2 over-
expression/gene amplification compared with the IDC
group (ER-, 85% versus 45%, P <0.001; PR-, 82% versus
36%, P <0.001; HER2-, 84% versus 65%, P = 0.005). There
were significantly more triple-negative cases in the MBC
group compared with the IDC group (67% versus 17%,
P <0.001). Fewer patients received adjuvant hormonal
therapy in the MBC group than in the IDC group (24%
versus 68%, P <0.001). Over-expression of Ki-67 was more
common in the MBC group compared with the IDC
group (Ki-67 ≥14%, 87% versus 63%, P = 0.001).
The patients in the MBC group received more
radiotherapy and less hormonal therapy than those in
the IDC group (radiotherapy, 49% versus 23%, P <0.001;
hormonal therapy, 24% versus 68%, P <0.001). There was
no difference in the rates of chemotherapy and surgery
between the two groups. Sentinel lymph node (SLN)
biopsy in MBC was successful in eight of nine (89%)
patients. Negative SLNs (without metastasis in SLNs) were
found in seven of eight (87%) patients. In seven patients
with negative SLNs, no positive non-SLN was found. SLN
was not compared with IDC and TN-IDC due to small
patient numbers.
Table 2 gives the different locations of the recurrent
sites of MBC and IDC. Patients with local recurrence in the
MBC group presented more chest wall recurrence than
those in the IDC group (P = 0.038). Distant metastases
were significantly more likely to be in the lung in
patients with MBC but in the bone in patients with
IDC (P = 0.001).
Univariate analysis of the 5-year overall survival and
5-year disease-free survival
Figure 2A, B presents the 5-year OS and 5-year DFS curves
for MBC, IDC and TN-IDC. The prognosis was poorer for
MBC than for IDC and TN-IDC, with a 5-year OS rate of
54.5% in MBC versus 85.1% in IDC and 73.3% in TN-IDC
(P <0.001). The 5-year DFS rate was 45.5% in MBC versus
71.2%in IDC and 60.3% in TN-IDC (P <0.001).
Figure 1 Patient overview. Patients treated between 1991 and 2006 were selected from the database of the Breast Cancer. ASC,
adenosquamous carcinoma; COC, carcinoma with osseous and chondroid metaplasia; CS, carcinosarcoma; IDC, invasive ductal carcinoma; MBC,
metaplastic breast carcinoma;NTN, not triple-negative; SCC, squamous cell carcinoma; SPC, adenocarcinoma with spindle cell differentiation;
TN, triple-negative.
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Table 1 Clinicopathological features of metaplastic breast carcinoma, invasive ductal carcinoma and triple-negative
invasive ductal carcinoma
Metaplastic breast cancer (N = 55) Invasive ductal carcinoma (N = 767) TN-IDC (N = 131)
Features N (%) N (%) P N (%) P
Age 0.594 0.264
≤50 27 (49.09) 405 (52.80) 76 (58.02)
>50 28 (50.91) 362 (47.20) 55 (41.98)
Stage 0.001 <0.001
I 4 (7.27) 107 (13.95) 21 (16.03)
II 30 (54.55) 522 (68.06) 92 (70.23)
III 16 (29.09) 87 (11.34) 8 (6.11)
Unknown 5 (9.09) 51 (6.65) 10 (7.63)
Operation 0.051 0.054
Breast-conserving surgery 4 (7.27) 134 (17.47) 25 (19.08)
Modified radical mastectomy 51 (92.73) 633 (82.53) 106 (80.92)
Chemotherapy 0.302 0.295
Yes 48 (87.28) 627 (81.74) 106 (80.91)
No 7 (12.73) 140 (18.25) 25 (19.08)
Radiotherapy <0.001 <0.001
Yes 27 (49.09) 177 (23.08) 29 (22.14)
No 28 (50.91) 590 (76.92) 102 (77.86)
Hormone therapy <0.001
Yes 13 (23.64) 522 (68.06) —
No 42 (76.46) 245 (31.94) —
Pathological tumor stage <0.001 <0.001
T1 (≤2 cm) 5 (9.09) 317 (41.33) 58 (44.27)
T2 (2–5 cm) 22 (40.00) 332 (43.29) 55 (41.98)
T3 (>5 cm) 22 (40.00) 39 (5.08) 5 (3.82)
Tx 6 (10.91) 79 (10.30) 13 (9.92)
Pathological nodal stage 0.001 0.001
N0 35 (63.64) 314 (41.20) 50 (38.17)
N1-3 15 (27.27) 385 (49.93) 69 (52.67)
Nx 5 (9.09) 68 (8.87) 12 (9.16)
Histological grade 0.167 0.285
I or II 29 (52.73) 461 (60.10) 77 (58.78)
III 20 (36.36) 227 (29.60) 41 (31.30)
Unknown 6 (10.91) 79 (10.30) 13 (9.92)
Ki-67a <0.001 <0.001
≥14% 47 (87.27) 486 (63.36) 80 (61.07)
<14% 8 (12.73) 281 (36.64) 51 (38.93)
P53b 0.001 0.008
≥25% 28 (50.91) 221 (28.81) 40 (30.53)
<25% 27 (49.09) 546 (71.19) 91 (69.47)
Estrogen receptor <0.001
+ 8 (14.55) 419 (54.63) —
− 47 (85.45) 348 (45.37) —
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Figure 2C, D presents the 5-year OS and 5-year DFS
curves for TN-IDC and MBC subtypes. The prognosis of
TN-IDC was better than any subtype of MBC, with a
5-year OS rate of 73.3% in TN-IDC versus 50.0% in
SCC, 56.3% in ASC, 40.0% in SPC and 75.0% in CS
(P = 0.039). With regards the 5-year OS, SPC had the
worst prognosis of the MBC subtypesand CS had the best.
Looking at the 5-year DFS, patients with SCC showed
more recurrence (35.7%) than those with TN-IDC (59.5%),
ASC (50.0%), SPC (41.7%) and CS (50.0%), although
P values of 5-year DFS (P = 0.254) were not significant.
Multivariate analysis of the 5-year overall survival and
5-year disease-free survival in metaplastic breast cancer
Multivariate analysis (Table 3) revealed that 5-year OS
and 5-year DFS were significantly related to tumor size
larger than 5.0 cm (5-year OS: hazard ratio (HR) 3.22,
95% CI 1.32 to 7.89, P = 0.010; 5-year DFS: HR 2.96,
95% CI 1.19 to 7.39, P = 0.020) and lymph node
involvement (5-year OS: HR 3.17, 95% CI 1.31 to
7.67, P = 0.010; 5-year DFS: HR 1.59, 95% CI 1.08 to
2.35, P = 0.018). Furthermore, both 5-year OS and
5-year DFS were significantly related to Ki-67 ≥14%
(5-year OS: HR 2.93, 95% CI 1.08 to 7.96, P = 0.035;
5-year DFS: HR 2.72, 95% CI 1.00 to 7.41, P = 0.049).
Systemic therapy
Of the 55 patients with MBC, 48 received adjuvant
chemotherapy. Table 4 details the adjuvant chemotherapy
regimens administered to these patients along with the
treatment outcomes. In 15 of these 48 patients, radiation
therapy was administered subsequent to chemotherapy;
in two of these patients, further disease progression
occurred, with isolated recurrences to the chest wall (four
months after primary therapy) and liver (six months after
primary therapy). At last follow-up of the 55 patients with
MBC, 33 had experienced disease relapse, including 10
patients with locoregional recurrence, and 23 had experi-
enced distant metastasis. Of these 23 patients, 14 (60.9%)
had metastases to the lungs. The 23 patients were treated
with various chemotherapy regimens for metastatic
disease, including anthracyclines, carboplatin, taxanes,
capecitabine, vinorelbine and trastuzumab. Only five pa-
tients (21.7%) had a partial response to therapy, and five
patients (21.7%) had disease stabilization.
Radiotherapy
Of the 55 patients with MBC, 27were treated with
adjuvant radiation therapy. Five of these 27 patients had
a locoregional recurrence. The 5-year OS rate of the 28
patients without adjuvant radiation therapy was 40% and
the 5-year DFS rate was 60%, which were not different
from those of the patients treated with radiation
therapy. Fifteen patients received radiation therapy
for recurrent disease,and four patients had more than
one site irradiated. All patients experienced a partial
response or symptomatic improvement but, in five
patients, disease progression occurred within the irradiated
site (two locoregional, one lung, one meningeal and bone)
in an average of 4 months.
Table 1 Clinicopathological features of metaplastic breast carcinoma, invasive ductal carcinoma and triple-negative
invasive ductal carcinoma (Continued)
Progesterone receptor <0.001
+ 10 (18.18) 492 (64.14) —
− 45 (81.82) 276 (35.98) —
Human epidermal growth factor receptor-2 0.005
+ 9 (16.36) 268 (34.94) —
− 46 (83.64) 499 (65.06) —
TN-MBC 37 (67.27) 131 (18.22) <0.001 —
Not TN-MBC 18 (32.73) 636 (81.78) —
aMedian value for Ki-67 = 13.96, bMedian value for P53 = 24.85. TN-MBC, triple-negative metaplastic breast carcinoma; TN-IDC, triple-negative invasive
ductal carcinoma.
Table 2 The different locations of the recurrent sites of
metaplastic breast carcinoma and invasive ductal
carcinoma
Recurrent sites MBC (N = 33) IDC (N = 222) P
Local recurrence 10 27 0.038
Chest wall 10 (100%) 18 (67%)
Axillary fossa 0 9 (33%)
Distant metastasis 23 193 0.001
Lung and pleura 14 (61%) 50 (26%)
Liver 4 (17%) 15 (8%)
Bone 4 (17%) 116 (60%)
Brain and meninges 1 (4%) 12 (6%)
Others 0 2
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Figure 2 Survival curves. (A) Five-year OS curves based on MBC, IDC and TN-IDC. (B) Five-year DFS curves based on MBC, IDC and TN-IDC.
(C) Five-year OS curves for SCC, ASC, SPC, CS and TN-IDC. (D) Five-year DFS curves for SCC, ASC, SPC, CS and TN-IDC.ASC, adenosquamous
carcinoma; CS, carcinosarcoma; DFS, disease-free survival; IDC, Invasive ductal carcinoma; MBC, metaplastic breast carcinoma; OS, overall survival;
SCC, squamous cell carcinoma; SPC, adenocarcinoma with spindle cell differentiation; TN-IDC, triple-negative invasive ductal carcinoma; TN-MBC,
triple-negative metaplastic breast carcinoma.
Table 3 Multivariate analysis of 5-year overall survival and 5-year disease-free survival in metaplastic breast cancer
5-year OS 5-year DFS
HR 95% CI P HR 95% CI P
Pathological tumor stage (>T3) 3.224 1.32 to 7.89 0.010 2.962 1.19 to 7.39 0.020
Pathological nodal stage (positive) 3.170 1.31 to 7.67 0.010 1.594 1.08 to 2.35 0.018
Histological grade (3) 0.945 0.24 to 3.70 0.935 1.066 0.28 to 4.07 0.925
P53 (≥25%) 3.274 0.40 to 26.72 0.268 3.413 0.43 to 27.38 0.248
Ki-67 (≥14%) 2.926 1.08 to 7.96 0.035 2.719 1.00 to 7.41 0.049
Hormone therapy (yes) 0.290 0.06 to 1.42 0.126 0.341 0.07 to 1.68 0.185
Subtypes of MBC (SPC) 1.388 0.54 to 3.59 0.499 — — —
MBC, metaplastic breast cancer;SPC, adenocarcinoma with spindle cell differentiation.
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Hormonal therapy
Of the 55 patients with MBC, 13were treated with
tamoxifen as adjuvant treatment. Of these 13 patients,
8 (61.5%) are currently alive and relapse-free. Tamoxifen
was used for two patients with metastases, one of whom
had an ER-positive tumor, but neither of these patients
responded to the treatment.
Discussion
MBC is a rare disease that accounts for less than 1% of
all mammary tumors [1]. In our study, the incidence rate
of MBC was only 0.73%. Interestingly, we found that
an increasing number of patients with MBC were
reported each year. The World Health Organization
only recognized MBC as a distinct pathological
entity in 2000. The increased incidence we noted
may represent an actual increase in the disease.
Alternatively, it may be a result of improved awareness and
recognition by pathologists [4,5], who, since the early
immunohistochemical reports more than 10 years ago
[16], have increasingly recognized and reported this
distinct histologic type of breast cancer. However, because
of its rarity, only relatively small series have been reported.
The prognosis of MBC had not been well delineated.
Although some investigators have reported a better progno-
sis for MBC than IDC, others had reported that the prog-
nosis for MBC was unfavorable compared to IDC [4,17,18].
We observed a dismal prognosis for patients with MBC
when compared with 767 patients with IDC, including 131
patients with TN-IDC. Most previous studies have found
that the tumor was large at the time of MBC diagnosis.
The median tumor size in our study was 5.0 cm (range, 1.5
to 20.0 cm), larger than the size of an IDC (median 2.3 cm)
or TN-IDC (median 2.1 cm). Pezziet al. [4] reported that
the larger sizes of MBC at clinical presentation appeared to
result from a more rapid growth rate.
MBC presented with axillary nodal involvement less
frequently than did IDC of the breast. Only 15 of the 55
patients with MBC (27%) had nodal involvement in our
study. These data were consistent with previous reports
that showed incidences of axillary nodal involvement at
diagnosis of MBC between 6% and 28% [19-21]. MBC
was usually associated with a lower incidence of axillary
nodal involvement than that of an IDC with similar size.
Patients with MBC had a median tumor size of 5.0 cm.
Data from patients with an adenocarcinoma of the
breast without metaplasia suggested that, for tumors
ranging in size from 2.0 to 4.0 cm, the expected
frequency of axillary node involvement was greater
than 50% [12]. In our study, only nine of 40 patients
with MBC (22%) with tumor sizes between 3.0 and
5.0 cm were axillary node-positive. SLN biopsy was
adaptive in patients with MBC before axillary lymph
node dissection. Despite MBC being less likely to
present with positive axillary lymph nodes, the risk
of developing metastatic disease was greater than in
typical adenocarcinoma of the breast. It was believed
that hematogenous spread was more common in
MBC. The above data support the concept that MBC
is an aggressive tumor with a high risk of recurrence
following the primary site therapy.
In our study, there was a very low incidence of hormone
receptor positivity in MBC compared to IDC. Hormonal
therapy was rarely provided to patients with MBC, consist-
ent with the low incidence of hormone receptor positivity
in these patients. Rosen [22] noted that the lack of ER and
PR might be due to the absence of a prominent glandular
epithelial compartment in these tumors. Previous studies
have found HER2 over-expression ranging from 4% to 17%
[9,23]. In our study, nine of 35 patients with MBC (26%)
had HER2 over-expression, consistent with previous studies.
Triple-negative cases accounted for 67% of MBC, within
the range of previous studies, where 64% to 96% of patients
with MBC showed triple-negativity [5,9].
Notably, mastectomy was performed more often for
patients with MBC. This was likely due to a larger tumor:
Table 4 Adjuvant chemotherapy regimens and relapses in 48 patients with metaplastic breast cancer
Chemotherapy regimen Number Patient outcome
Cyclophosphamide, methotrexate and fluorouracil 7 Seven relapsed.
(Fluorouracil), doxorubicin/anthracyclines and cyclophosphamide 7 Two relapse-free at 45 and 57 months. One alive and well at
62 months after a local recurrence. Two progressed while
receiving adjuvant therapy. Two relapsed.
(Fluorouracil), doxorubicin/anthracyclines and cyclophosphamide to
taxane, paclitaxel/cisplatin/carboplatin
9 Five relapse-free at 30, 53, 66, 69 and 101 months respectively.
Four relapsed.
Taxane/paclitaxel, anthracyclines and cyclophosphamide 18 Eight relapse-free at 55, 64, 75, 91, 108, 110, 123 and
156 months respectively. Ten relapsed.
Taxane, anthracyclines and cyclophosphamidein combination
with cisplatin/capecitabine
4 Three alive and well at 17, 25 and 39 months after a local recurrence.
One alive at 45 months before a local recurrence, alive at 20 months
after distant metastasis.
Paclitaxel, anthracyclines and cyclophosphamidein combination
with capecitabine/vinorelbine
3 Three alive at 24, 29 and 41 months before a local recurrence, alive at
15, 18 and 25 months after distant metastasis.
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tumor size was >5 cm in 40% of patients with MBC
compared with only 5% of patients with IDC. As a
consequence of the lower rate of breast conservation
and less nodal involvement, postoperative radiation therapy
was performed less often for patients with MBC; however,
these patients underwent chemotherapy more often
due to their negative hormone receptor status and
larger tumor size. In our study, patients who underwent
mastectomy had an unfavorable survival rate during the
follow-up period.
Recently, significant progress had been made in the field
of MBC biology, which could hypothetically explain its far
more aggressive nature compared with other triple-negative
breast cancers. Lien et al. [24] elucidated and validated that
the epithelial-mesenchymal transition-related genes were
differentially up-regulated in MBC compared with IDC,
and Hennessy et al. [25] demonstrated that MBC was
distinct from basal-like cancers. MBC showed a close
relationship with basal-like cancers and a novel subgroup
of receptor-negative breast cancers. The patients with
the features of both MBC and basal-like cancers had
enrichment for stem cell-like markers with an elevation of
CD29/CD24 and CD44/CD24 ratios.
Further research on the mechanisms of carcinogenesis
and the potential importance of new molecular markers
(for example, P63, Zinc Finger E-box Binding Homeobox
1 (ZEB1), B-cell lymphoma 2 (Bcl-2)) are needed to
develop better prognostic factors for this disease. If our
data were confirmed, patients with MBC, particularly
those with metastatic disease, would be appropriate candi-
dates for clinical trials evaluating new combinations of the
active chemotherapy agents for breast cancer. Considering
the differences in the clinical and biologic behavior of
these tumors compared with IDC and TN-IDC, clinical
trials designed specifically for MBC would be very helpful
to further characterize the biology and therapy of this
disease. In this study, the number of MBC cases is too
small to convincingly determine the prognostic factors
that affect treatment outcomes of MBC compared with
IDC, therefore more cases and longer follow-up may be
necessary for this type of analysis.
Conclusions
MBC had distinct clinicopathological features, which
include a larger tumor size at presentation, higher
Ki-67proliferation index, and a higher proportion of
ER-negative and/or PR-negative tumors compared to
IDC and TN-IDC. Our study demonstrated that MBC
was an extremely aggressive disease and showed poorer
prognosis compared with general IDC and TN-IDC. We
found that better systemic treatment was required to
prevent recurrence. Poor prognostic indicators for MBC
include a tumor size larger than 5.0 cm, lymph node
involvement and Ki-67 ≥14%.
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